Literature DB >> 30838293

Antisense Oligonucleotide Therapy for Spinocerebellar Ataxias: Good News for Terrible Diseases.

Hélio A G Teive1, Carlos Henrique F Camargo2, Renato Puppi Munhoz3.   

Abstract

Entities:  

Year:  2018        PMID: 30838293      PMCID: PMC6336412          DOI: 10.1002/mdc3.12627

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN: 2330-1619


× No keyword cloud information.
  4 in total

1.  Generation and characterization of Sca2 (ataxin-2) knockout mice.

Authors:  Tim-Rasmus Kiehl; Alex Nechiporuk; Karla P Figueroa; Mark T Keating; Duong P Huynh; Stefan-M Pulst
Journal:  Biochem Biophys Res Commun       Date:  2005-11-08       Impact factor: 3.575

2.  Professor Wadia's contributions to neurology and spinocerebellar ataxia type 2.

Authors:  Fernando Spina Tensini; José Luiz Pedroso; Orlando G P Barsottini; Hélio A G Teive
Journal:  Arq Neuropsiquiatr       Date:  2017-04       Impact factor: 1.420

Review 3.  Spinocerebellar Ataxia Type 2.

Authors:  Daniel R Scoles; Stefan M Pulst
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

4.  Antisense oligonucleotide therapy for spinocerebellar ataxia type 2.

Authors:  Daniel R Scoles; Pratap Meera; Matthew D Schneider; Sharan Paul; Warunee Dansithong; Karla P Figueroa; Gene Hung; Frank Rigo; C Frank Bennett; Thomas S Otis; Stefan M Pulst
Journal:  Nature       Date:  2017-04-12       Impact factor: 49.962

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.